Metformina + Vildagliptina Sandoz

Metformin Hydrochloride, the active ingredient in Metformina + Vildagliptina Sandoz, is a Biguanide/DPP-4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults when diet, exercise and monotherapy are insufficient.

GNH USA supplies Metformina + Vildagliptina Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Vildagliptina is an oral antidiabetic combination that targets hyperglycaemia in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves overall glycaemic control and reduces HbA1c when added to diet, exercise and other therapies. - Adjunct to metformin monotherapy: provides additional glucose‑lowering effect in patients not achieving targets with metformin alone. - Combination therapy with other oral agents: offers a complementary mechanism to sulfonylureas, SGLT2 inhibitors or insulin, helping to achieve tighter glucose control.

The combination may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea. - Headache: mild to moderate intensity. - Metallic taste: transient alteration of taste perception.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication associated with metformin. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain and elevated enzymes. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: abnormal liver enzymes or hepatic failure.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal function assessment: ensure adequate creatinine clearance before prescribing. - Hepatic function monitoring: check liver enzymes periodically. - Lactic acidosis risk: avoid in patients with severe infection, hypoxia, or dehydration. - Caution in elderly: dose adjustments may be needed due to reduced renal reserve. - Concomitant antidiabetic agents: monitor for additive hypoglycaemic effect. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformina + Vildagliptina may interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Iodinated contrast agents: can precipitate acute renal failure, increasing metformin accumulation. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise vildagliptin plasma levels. - Cimetidine or trimethoprim: can reduce metformin clearance, heightening lactic acidosis risk.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal function and alter metformin excretion. - Beta‑blockers: can mask hypoglycaemia symptoms. - NSAIDs: may impair renal perfusion, necessitating renal function checks.